T1	Participants 52 128	postmenopausal women with advanced, hormone-receptor-positive breast cancer:
T2	Participants 464 517	patients with hormone-receptor-positive breast cancer
T3	Participants 539 589	phase 2 trial in outpatient clinics and hospitals.
T4	Participants 602 744	postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment.
T5	Participants 1437 1536	We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
T6	Participants 1966 2126	most common grade 3 or higher adverse event was neutropenia-reported by six of 106 (6%) patients in the ganitumab group and one of 49 (2%) in the placebo group.
T7	Participants 2127 2436	Hyperglycaemia was reported by 12 of 106 (11%) patients in the ganitumab group (with six patients having grade 3 or 4 hyperglycaemia) and none of 49 in the placebo group. Serious adverse events were reported by 27 of 106 (25%) patients in the ganitumab group and nine of 49 (18%) patients in the placebo group
